The WACC of Kiadis Pharma NV (KDS.AS) is 6.7%.
| Range | Selected | |
| Cost of equity | 4.70% - 8.80% | 6.75% |
| Tax rate | -% - 0.10% | 0.05% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 4.7% - 8.6% | 6.7% |
| Category | Low | High |
| Long-term bond rate | 2.3% | 2.8% |
| Equity market risk premium | 6.6% | 7.6% |
| Adjusted beta | 0.36 | 0.72 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 4.70% | 8.80% |
| Tax rate | -% | 0.10% |
| Debt/Equity ratio | 0.06 | 0.06 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 4.7% | 8.6% |
| Selected WACC | 6.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for KDS.AS:
cost_of_equity (6.75%) = risk_free_rate (2.55%) + equity_risk_premium (7.10%) * adjusted_beta (0.36) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.